Author:
Liu Yang,Li Qian,Liu Ying,Qiao Pengyan,Liu Sumiao,Xu Ke
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Lai CC, Chen WS, Chang YS, Wang SH, Huang CJ, Guo WY et al (2013) Clinical features and outcomes of posterior reversible encephalopathy syndrome in patients with systemic lupus erythematosus. Arthritis Care Res 65(11):1766–1774
2. Cui HW, Lei RY, Zhang SG, Han LS, Zhang BA (2019) Clinical features, outcomes and risk factors for posterior reversible encephalopathy syndrome in systemic lupus erythematosus: a case-control study. Lupus 28(8):961–969
3. Mak A, Chan BP, Yeh IB, Ho RC, Boey ML, Feng PH et al (2008) Neuropsychiatric lupus and reversible posterior leucoencephalopathy syndrome: a challenging clinical dilemma. Rheumatology 47(3):256–262
4. Hao DL, Yang YL, Zhou LM, Liu QH, Liu R, Xu K et al (2021) Systemic lupus erythematosus complicated with reversible posterior encephalopathy syndrome: a case report. J Int Med Res 49(7):3000605211029766
5. Zhang L, Xu J (2018) Posterior reversible encephalopathy syndrome (PRES) attributed to mycophenolate mofetil during the management of SLE: a case report and review. Am J Clin Exp Immunol 7(1):1–7